Transcat, Inc. (TRNS) AI Stock Analysis

Transcat, Inc. provides calibration and laboratory instrument services across the United States, Canada, and internationally through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting services, and proprietary software solutions such as CalTrak and the Compliance, Control and Cost online asset management portal. The Distribution segment sells and rents test, measurement, and control instruments, while providing calibration certification, rentals, used equipment sales, and kitting. Transcat serves highly regulated industries, primarily life sciences including pharmaceuticals, biotechnology, and medical devices, as well as aerospace, defense, manufacturing, energy, and utilities.

Transcat achieved a 5-year revenue CAGR of 13.9% from FY2021 to FY2026. Annual revenue expanded from $205.0M in FY2022 to $331.9M in FY2026, rising 19.2% in FY2026 alone. However, net income decreased from $14.5M in FY2025 to $5.4M in FY2026, as operating margin compressed to 4.0% and net margin dropped to 1.6%. In the trailing twelve months, revenue reached $348.4M with a 1.0% profit margin and EPS of $0.36. In the latest quarter ended June 30, 2026, quarterly revenue increased 21.6% year-over-year, while quarterly earnings declined 60.0%.

As of June 30, 2026, Transcat held $6.7M in cash and short-term investments against total debt of $143.2M, resulting in net debt of $136.5M. Total assets were $492.6M and shareholders' equity was $302.9M, yielding a debt-to-equity ratio of 0.47 and a current ratio of 2.49. For FY2026, the company generated $34.9M in operating cash flow and $19.6M in free cash flow, deploying $15.3M toward capital expenditures and $469,000 toward share buybacks.

At $80.35 per share, Transcat has a market capitalization of $752.1M and an enterprise value of $971.2M. The stock trades at a trailing P/E of 223.2x and a forward P/E of 50.8x, compared to medians of 24.8x and 17.2x for its US-listed Industrials peers. Its EV/EBITDA of 25.0x also sits above the peer median of 13.9x. Transcat shares returned 14.9% over the past year and 13.5% over five years, trailing the S&P 500 benchmark returns of 16.8% and 83.0% over the same periods.

Transcat holds 2 Strong Buy and 2 Hold ratings from analysts, with no Buy, Sell, or Strong Sell recommendations. The mean price target is $104.33, representing 29.8% upside from the last close of $80.35. For the current fiscal year ending March 31, 2027, consensus estimates project revenue of $372.9M and EPS of $1.90, reflecting 3.0% EPS growth. Over the last four quarters, the company beat EPS estimates 1 time. The next earnings date is November 2, 2026.

This page is an AI-written research summary of Transcat, Inc. (TRNS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TRNS income statement, TRNS balance sheet, TRNS key metrics, TRNS analyst forecast, TRNS chart. See the TRNS stock overview for the latest quote and news.